The two companies will work together to evaluate the potential of OrionAI – a revolutionary AI-based diagnostic assistant for histological examination of various solid nodes. Head and neck squamous cell carcinoma (HNSCC) Cancer.
HNSCC is the most prevalent cancer in India, and the two companies have decided to collaborate to tackle a disease that presents a unique healthcare challenge for India. This partnership will help researchers facilitate collaboration, centralized review, training, image viewing and analysis, and at the same time improve the assessment of standard pathological symptoms.
In the field of healthcare, AI and machine learning have shown promising results across many domains. The use of technology and algorithms owned by Croscope has a great deal to do with the global cancer burden. The way workflows are set around the world, there is a huge supply gap in the number of trained pathologists needed. By increasing the capacity of pathologists, CrossScope and Forecast aim to speed up diagnosis, significantly reduce turnaround times (TAT) and reduce the rate of misdiagnosis by taking advantage of the digitization of pathology.
Digital pathology uses predefined algorithms to generate continuous and rapid histopathological analysis, leading to significant advances in the validation and identification of various markers capable of predicting disease progression, patient prognosis, and treatment response. The combination of digital pathology with other emerging technologies, such as artificial intelligence and machine learning, demonstrates a strong commitment to identifying predictive biomarkers for certain types of cancer.
The main objective of this collaboration is to evaluate the ability of advanced deep learning technology of Croscope to detect and quantify major tumor pathology hallmarks from digitized H&E slides and compare them with the evaluation of trained pathologists and their correlations when compared.
This will further demonstrate the performance of the crossscope’s algorithms that are adaptable to independent test sets, images and various slide tissue materials, making it a flexible, general purpose and adaptive method in both clinical and research settings.
“Based on the deep learning of the Croscope OrionAITM Digitized slides from cancer biopsies are dedicated to accurately detecting and evaluating clinically relevant findings. This collaboration will accelerate the discovery of medicine and improve the power of digital transformation in driving new breakthroughs, which will help in better diagnosis of cancer. We are excited to work with Mohit and his team at Forecast Biosciences to bring the latest tools for precision diagnosis, “said Dr. Jayendra Shinde, CEO of CrossScope.
Satish Sankaran, CSO, Forecast Bioscience, said, “Forecast time (Tumor Immune Microenvironment) Is a human tumor microenvironment platform that demonstrates the maintenance of all elements of the human tumor microenvironment for 72 hours. Digitization and evaluation of AI-based histopathology will go a long way in improving the speed, efficiency and robustness of our pathology workflow. “
Mohit Malhotra, CEO of Farkast Biosciences, added, “Histopathology is one of the pillars of our multidimensional examination system. Is their pipeline candidates. “
